



(51) International Patent Classification:

C07K 16/10 (2006.01)

(21) International Application Number:

PCT/EP2018/073489

(22) International Filing Date:

31 August 2018 (31.08.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/EP2017/071891

31 August 2017 (31.08.2017) EP

(71) Applicant: **HUMABS BIOMED SA** [CH/CH]; Via Mirasole 1, 6500 Bellinzona (CH).

(72) Inventor: **CORTI, Davide**; Via Mirasole 1, 6500 Bellinzona (CH).

(74) Agent: **VON STOSCH, Andreas** et al.; Prinzregentenstr. 22, 80538 München (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF

(57) Abstract: The invention relates to multispecific antibodies, and antigen binding fragments thereof, that specifically bind to distinct Zika virus epitopes and potentially neutralize infection of ZIKV. The invention also relates to nucleic acids that encode such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in prophylaxis and treatment of ZIKV infection.



From the INTERNATIONAL BUREAU

PCTNOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

To:

VON STOSCH, Andreas
Prinzregentenstr. 22
80538 München
ALLEMAGNE

Date of mailing (day/month/year) 27 January 2020 (27.01.2020)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference HB01P034WO1	
International application No. PCT/EP2018/073489	International filing date (day/month/year) 31 August 2018 (31.08.2018)

1. The following indications appeared on record concerning:		
☒ the applicant	☐ the inventor	☐ the agent
☐ the common representative		
Name and Address HUMABS BIOMED SA Via Mirasole 1 6500 Bellinzona Switzerland	State of Nationality CH	State of Residence CH
	Telephone No.	
	Facsimile No.	
	E-mail address	
2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:		
☐ the person	☐ the name	☒ the address
☐ the nationality		
☐ the residence		
Name and Address HUMABS BIOMED SA Via dei Gaggini 3 6500 Bellinzona Switzerland	State of Nationality CH	State of Residence CH
	Telephone No.	
	Facsimile No.	
	E-mail address ☐ Notifications by e-mail authorized	
3. Further observations, if necessary:		
4. A copy of this notification has been sent to:		
☒ the receiving Office	☐ the International Preliminary Examining Authority	
☒ the International Searching Authority	☒ the designated Offices concerned	
☐ the Authority(ies) specified for supplementary search	☐ the elected Offices concerned	
	☐ other:	

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Righetto Norbert e-mail pct.team5@wipo.int Telephone No. +41 22 338 74 05
---	--